Literature DB >> 18251982

Long-term outcome of a covered vs. uncovered transjugular intrahepatic portosystemic shunt in Budd-Chiari syndrome.

Sarwa Darwish Murad1, Trinh K Luong, Peter M T Pattynama, Bettina E Hansen, Henk R van Buuren, Harry L A Janssen.   

Abstract

BACKGROUND: The clinical outcome of a covered vs. uncovered transjugular intrahepatic portosystemic shunt (TIPS) for patients with Budd-Chiari syndrome (BCS) is as yet largely unknown.
OBJECTIVES: To compare patency rates of bare and polytetrafluoroethylene (PTFE)-covered stents, and to investigate clinical outcome using four prognostic indices [Child-Pugh score, Rotterdam BCS index, modified Clichy score and Model for End-Stage Liver Disease (MELD)].
METHODS: Consecutive patients with BCS who had undergone TIPS between January 1994 and March 2006 were evaluated in a retrospective review in a single centre.
RESULTS: Twenty-three TIPS procedures were performed on 16 patients. The primary patency rate at 2 years was 12% using bare and 56% using covered stents (P=0.09). We found marked clinical improvement at 3 months post-TIPS as determined by a drop in median Child-Pugh score (10-7, P=0.04), Rotterdam BCS index (1.90-0.83, P=0.02) and modified Clichy score (7.77-2.94, P=0.003), but not in MELD (18.91-17.42, P=0.9). Survival at 1 and 3 years post-TIPS was 80% (95% CI: 59-100%) and 72% (95% CI: 48-96%). Four patients (25%) died and one required liver transplantation.
CONCLUSIONS: A transjugular intrahepatic portosystemic shunt using PTFE-covered stents shows better patency rates than bare stents in BCS. Moreover, TIPS leads to an improvement in important prognostic indicators for the survival of patients with BCS.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18251982     DOI: 10.1111/j.1478-3231.2007.01649.x

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  13 in total

1.  Bacteremia and "Endotipsitis" following transjugular intrahepatic portosystemic shunting.

Authors:  Meir Mizrahi; Lilach Roemi; Daniel Shouval; Tomer Adar; Maya Korem; Alon Moses; Alan Bloom; Oren Shibolet
Journal:  World J Hepatol       Date:  2011-05-27

Review 2.  Selection of a TIPS stent for management of portal hypertension in liver cirrhosis: an evidence-based review.

Authors:  Xing-Shun Qi; Ming Bai; Zhi-Ping Yang; Dai-Ming Fan
Journal:  World J Gastroenterol       Date:  2014-06-07       Impact factor: 5.742

3.  Multicenter analysis of the use of transjugular intrahepatic portosystemic shunt for management of MPN-associated portal hypertension.

Authors:  Christopher R Reilly; Daria V Babushok; Karlyn Martin; Jerry L Spivak; Michael Streiff; Ranjeeta Bahirwani; Jeffrey Mondschein; Brady Stein; Alison Moliterno; Elizabeth O Hexner
Journal:  Am J Hematol       Date:  2017-07-26       Impact factor: 10.047

Review 4.  Budd-Chiari syndrome and liver transplantation.

Authors:  Nobuhisa Akamatsu; Yasuhiko Sugawara; Norihiro Kokudo
Journal:  Intractable Rare Dis Res       Date:  2015-02

5.  Transjugular intrahepatic portocaval shunt placed through the strut of an inferior vena cava stent in a patient with Budd-Chiari syndrome: a technical modification.

Authors:  N R S Surendrababu; S N Keshava; C E Eapen; U G Zachariah
Journal:  Br J Radiol       Date:  2010-01       Impact factor: 3.039

6.  Treatment of Budd-Chiari syndrome with a focus on transjugular intrahepatic portosystemic shunt.

Authors:  Anders Bay Neumann; Stine Degn Andersen; Dennis Tønner Nielsen; Peter Holland-Fischer; Hendrik Vilstrup; Henning Grønbæk
Journal:  World J Hepatol       Date:  2013-01-27

7.  A single-institution review of portosystemic shunts in children: an ongoing discussion.

Authors:  J B Lillegard; A M Hanna; T J McKenzie; C R Moir; M B Ishitani; D M Nagorney
Journal:  HPB Surg       Date:  2010-05-06

8.  Fifteen years' experience with transjugular intrahepatic portosystemic shunt (TIPS) using bare stents: retrospective review of clinical and technical aspects.

Authors:  C Gazzera; D Righi; F Valle; A Ottobrelli; M Grosso; G Gandini
Journal:  Radiol Med       Date:  2008-12-11       Impact factor: 3.469

9.  Budd-Chiari syndrome: consensus guidance of the Asian Pacific Association for the study of the liver (APASL).

Authors:  Akash Shukla; Ananta Shreshtha; Amar Mukund; Chhagan Bihari; C E Eapen; Guohong Han; Hemant Deshmukh; Ian Homer Y Cua; Cosmas Rinaldi Adithya Lesmana; Mamun Al Meshtab; Masayoshi Kage; Roongruedee Chaiteeraki; Sombat Treeprasertsuk; Suprabhat Giri; Sundeep Punamiya; Valerie Paradis; Xingshun Qi; Yasuhiko Sugawara; Zaigham Abbas; Shiv Kumar Sarin
Journal:  Hepatol Int       Date:  2021-07-08       Impact factor: 6.047

10.  MRI-monitored intra-shunt local agent delivery of motexafin gadolinium: towards improving long-term patency of TIPS.

Authors:  Han Wang; Feng Zhang; Yanfeng Meng; Tong Zhang; Patrick Willis; Thomas Le; Stephanie Soriano; Erik Ray; Karim Valji; Guixiang Zhang; Xiaoming Yang
Journal:  PLoS One       Date:  2013-02-28       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.